The Unintended Consequences of Medical Progress: Why Pharmac's Drug Backlog Is a Symptom, Not a Crisis
Here’s a paradox worth unpacking: The very innovations designed to save lives are creating a bureaucratic bottleneck that could delay access to those same treatments. Pharmac’s drug approval backlog isn’t just a funding issue—it’s a collision of medical progress, political inertia, and demographic reality. And if we’re not careful, the cure for this problem might end up harming the patients it aims to protect.
The Backlog That Never Sleeps
Let’s start with the numbers, even though they’re less interesting than the story behind them. Pharmac’s ‘options for investment’ list currently holds over 100 drugs, but advocacy groups warn this could balloon to 400 within 24 months. Why? Because modern medicine isn’t just advancing—it’s accelerating. New therapies emerge faster than any agency can evaluate them, creating a perpetual game of catch-up. Malcolm Mulholland of Patient Voice Aotearoa frames this as a political failure, but what he’s really describing is a systemic mismatch between innovation timelines and bureaucratic processes. Politicians can’t ‘tackle’ this issue with a single policy fix because the problem isn’t static. It’s metastasizing.
The Efficiency Trap
Pharmac’s decision to streamline its assessment process feels like a smart move—until you realize efficiency creates its own demand. Think about it: If you reduce evaluation times, you’ll approve more drugs faster. But faster approval just means more drugs qualify for funding consideration, which requires… more funding. It’s the healthcare equivalent of the Red Queen’s race—running faster to stay in the same place. Dr. David Hughes boasts about hiring more economists and tweaking workflows, but these are incremental changes in a system where the finish line keeps moving. What’s missing? A radical rethinking of priorities. Should Pharmac focus on blockbuster drugs for aging populations or niche therapies for rare diseases? The current model avoids answering this uncomfortable question.
Funding: The Illusion of Generosity
Minister David Seymour claims his government has delivered “record funding increases,” which sounds impressive until you dissect the math. If budgets rise 5% annually but drug applications grow at 20%, you’re not solving a crisis—you’re just slowing the collapse. This raises a deeper issue: Politicians love announcing new healthcare funding because it plays well electorally, but no one wants to explain the arithmetic that makes their promises unsustainable. Aging populations aren’t just a New Zealand problem—they’re a global demographic shift. Yet every nation treats this as a surprise, scrambling to fund treatments for diseases we’ve known would dominate elderly populations for decades.
The Hidden Cost of Hope
Here’s a psychological angle most miss: Every drug added to Pharmac’s wishlist creates a new cohort of patients who believe they’re entitled to a treatment they might never receive. This isn’t cynicism—it’s a reality of managed healthcare. When you publicize a ‘wish list,’ you dangle hope in front of people, only to let bureaucracy and budget constraints dash it later. I’m not suggesting Pharmac stop publishing these lists, but we need honest conversations about the emotional toll of unmet expectations. How many families are clinging to the possibility of a drug that’ll never clear the funding hurdle? And what does that mean for public trust in healthcare institutions?
A Thought Experiment: What If We Fund Everything?
Let’s play devil’s advocate. Suppose New Zealand somehow found the resources to fund all 400+ drugs on Pharmac’s horizon. Would that solve the problem? Unlikely. Pharmaceutical companies would respond by developing even more treatments, knowing the system has (temporarily) loosened its purse strings. This is the law of unintended consequences: Expand capacity, and demand will rise to exceed it. The real issue isn’t funding levels—it’s our cultural obsession with treating medical innovation as inherently good, without asking whether society can sustain its own creations.
Final Reflection: The Future Isn’t Just Expensive—It’s Existentially Complex
What keeps me awake isn’t the 400-drug projection but what it symbolizes: We’re building a healthcare system where miracles become expectations, and expectations outpace reality. Until we confront the ethical quagmire of rationing cutting-edge treatments—or fundamentally rethink how we fund medical innovation—we’ll keep rearranging chairs on the Pharmac Titanic. The next government might throw more money at the problem, but without grappling with the deeper paradoxes of progress, we’re just writing prescriptions we can’t afford to fill.
